TY - JOUR
T1 - ChIP-seq in studying epigenetic mechanisms of disease and promoting precision medicine
T2 - Progresses and future directions
AU - Yan, Huihuang
AU - Tian, Shulan
AU - Slager, Susan L.
AU - Sun, Zhifu
PY - 2016/9/1
Y1 - 2016/9/1
N2 - Chromatin immunoprecipitation followed by sequencing (ChIP-seq) is widely used for mapping histone modifications, histone proteins, chromatin regulators, transcription factors and other DNA-binding proteins. It has played a significant role in our understanding of disease mechanisms and in exploring epigenetic changes for potential clinical applications. However, the conventional protocol requires large amounts of starting material and does not quantify the actual occupancy, limiting its applications in clinical settings. Herein we summarize the latest progresses in utilizing ChIP-seq to link epigenetic alterations to disease initiation and progression, and the implications in precision medicine. We provide an update on the newly developed ChIP-seq protocols, especially those suitable for scare clinical samples. Technical and analytical challenges are outlined together with recommendations for improvement. Finally, future directions in expediting ChIP-seq use in clinic are discussed.
AB - Chromatin immunoprecipitation followed by sequencing (ChIP-seq) is widely used for mapping histone modifications, histone proteins, chromatin regulators, transcription factors and other DNA-binding proteins. It has played a significant role in our understanding of disease mechanisms and in exploring epigenetic changes for potential clinical applications. However, the conventional protocol requires large amounts of starting material and does not quantify the actual occupancy, limiting its applications in clinical settings. Herein we summarize the latest progresses in utilizing ChIP-seq to link epigenetic alterations to disease initiation and progression, and the implications in precision medicine. We provide an update on the newly developed ChIP-seq protocols, especially those suitable for scare clinical samples. Technical and analytical challenges are outlined together with recommendations for improvement. Finally, future directions in expediting ChIP-seq use in clinic are discussed.
KW - cancer
KW - ChIP-seq
KW - chromatin
KW - chromatin regulators
KW - epigenetic drugs
KW - histone modification
KW - transcription factor binding
UR - http://www.scopus.com/inward/record.url?scp=84986910744&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84986910744&partnerID=8YFLogxK
U2 - 10.2217/epi-2016-0053
DO - 10.2217/epi-2016-0053
M3 - Review article
C2 - 27319740
AN - SCOPUS:84986910744
SN - 1750-1911
VL - 8
SP - 1239
EP - 1258
JO - Epigenomics
JF - Epigenomics
IS - 9
ER -